Serial 98412294
Live / Applied — Second extension granted (statement of use) (as of 02 Dec 2025)
What this means for you
Not registered yet, but its 20 Feb 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98412294
- Mark type
- Design / logo
- Filed
- 20 Feb 2024
- Published for opposition
- 29 Oct 2024
- Attorney of record
- Peter Kunin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceuticals, namely, small molecule therapeutic preparations for the correction of RNA expression, used in the treatment of cancers, cardiovascular diseases, immunological diseases, autoimmune diseases, neuromuscular diseases, blood disorders, rare genetic disorders, fibrosis; pharmaceuticals used in the treatment of cancers, cardiovascular diseases, immunological diseases, autoimmune diseases, neuromuscular diseases, blood disorders, rare genetic disorders, fibrosis
Owner
- Skyhawk Therapeutics, Inc., Waltham, MA, US
- Skyhawk Therapeutics, Inc., Waltham, MA, US
Prior registrations
Prosecution history
- 03 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Dec 2025 — SOU EXTENSION 2 GRANTED
- 02 Dec 2025 — SOU EXTENSION 2 FILED
- 02 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 23 May 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 23 May 2025 — SOU EXTENSION 1 GRANTED
- 23 May 2025 — SOU EXTENSION 1 FILED
- 23 May 2025 — SOU TEAS EXTENSION RECEIVED
- 10 Dec 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 29 Oct 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 29 Oct 2024 — PUBLISHED FOR OPPOSITION
- 09 Oct 2024 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 23 Sept 2024 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 22 Sept 2024 — EXAMINER'S AMENDMENT ENTERED
- 22 Sept 2024 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED